These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 37951201

  • 1. Single-cell RNA-seq reveals novel immune-associated biomarkers for predicting prognosis in AML patients with RUNX1::RUNX1T1.
    Li XP, Dai Y, Zhang WN, Pan MM, Mao J, Zhao B, Jiang L, Gao Y.
    Int Immunopharmacol; 2023 Dec; 125(Pt B):111178. PubMed ID: 37951201
    [Abstract] [Full Text] [Related]

  • 2. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.
    Krauth MT, Eder C, Alpermann T, Bacher U, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S.
    Leukemia; 2014 Jul; 28(7):1449-58. PubMed ID: 24402164
    [Abstract] [Full Text] [Related]

  • 3. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.
    Qin YZ, Wang Y, Xu LP, Zhang XH, Chen H, Han W, Chen YH, Wang FR, Wang JZ, Chen Y, Mo XD, Zhao XS, Chang YJ, Liu KY, Huang XJ.
    J Hematol Oncol; 2017 Feb 06; 10(1):44. PubMed ID: 28166825
    [Abstract] [Full Text] [Related]

  • 4. Elucidation of Novel Therapeutic Targets for Acute Myeloid Leukemias with RUNX1-RUNX1T1 Fusion.
    Yun JW, Bae YK, Cho SY, Koo H, Kim HJ, Nam DH, Kim SH, Chun S, Joo KM, Park WY.
    Int J Mol Sci; 2019 Apr 06; 20(7):. PubMed ID: 30959925
    [Abstract] [Full Text] [Related]

  • 5. Myeloid translocation gene CBFA2T3 directs a relapse gene program and determines patient-specific outcomes in AML.
    Steinauer N, Guo C, Huang C, Wong M, Tu Y, Freter CE, Zhang J.
    Blood Adv; 2019 May 14; 3(9):1379-1393. PubMed ID: 31040112
    [Abstract] [Full Text] [Related]

  • 6. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.
    Rücker FG, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik VI, Jahn N, Schroeder T, Wattad M, Lübbert M, Koller E, Kindler T, Götze K, Ringhoffer M, Westermann J, Fiedler W, Horst HA, Greil R, Schroers R, Mayer K, Heinicke T, Krauter J, Schlenk RF, Thol F, Heuser M, Ganser A, Bullinger L, Paschka P, Döhner H, Döhner K.
    Blood; 2019 Nov 07; 134(19):1608-1618. PubMed ID: 31554635
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prognostic Role of Postinduction Minimal Residual Disease and Myeloid Sarcoma Type Extramedullary Involvement in Pediatric RUNX1-RUNX1T1 (+) Acute Myeloid Leukemia.
    Lee JW, Kim S, Jang PS, Chung NG, Cho B, Im SA, Kim M.
    J Pediatr Hematol Oncol; 2020 Apr 07; 42(3):e132-e139. PubMed ID: 31688618
    [Abstract] [Full Text] [Related]

  • 9. Identification of a Cryptic t(8;20;21)(q22;p13;q22) Resulting in RUNX1T1/RUNX1 Fusion in a Patient with Newly Diagnosed Acute Myeloid Leukemia.
    Macke EL, Meyer RG, Hoppman NL, Ketterling RP, Greipp PT, Xu X, Baughn LB, Shafer DA, He RR, Peterson JF.
    Lab Med; 2022 Jul 04; 53(4):e87-e90. PubMed ID: 34791328
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.
    Duployez N, Nibourel O, Marceau-Renaut A, Willekens C, Helevaut N, Caillault A, Villenet C, Celli-Lebras K, Boissel N, Jourdan E, Dombret H, Figeac M, Preudhomme C, Renneville A.
    Am J Hematol; 2014 Jun 04; 89(6):610-5. PubMed ID: 24616160
    [Abstract] [Full Text] [Related]

  • 12. Combination of eriocalyxin B and homoharringtonine exerts synergistic anti-tumor effects against t(8;21) AML.
    Lei YC, Chen XJ, Dai YT, Dai B, Wang JY, Li MH, Liu P, Liu H, Wang KK, Jiang L, Chen B.
    Acta Pharmacol Sin; 2024 Mar 04; 45(3):633-645. PubMed ID: 38017299
    [Abstract] [Full Text] [Related]

  • 13. Rearrangement of VPS13B, a causative gene of Cohen syndrome, in a case of RUNX1-RUNX1T1 leukemia with t(8;12;21).
    Abe A, Yamamoto Y, Katsumi A, Okamoto A, Tokuda M, Inaguma Y, Yamamoto K, Yanada M, Kanie T, Tomita A, Akatsuka Y, Okamoto M, Kameyama T, Mayeda A, Emi N.
    Int J Hematol; 2018 Aug 04; 108(2):208-212. PubMed ID: 29264741
    [Abstract] [Full Text] [Related]

  • 14. RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.
    Kim T, Moon JH, Ahn JS, Ahn SY, Jung SH, Yang DH, Lee JJ, Shin MG, Choi SH, Lee JY, Tyndel MS, Lee HY, Kim KH, Cai Y, Lee YJ, Sohn SK, Min YH, Cheong JW, Kim HJ, Zhang Z, Kim DDH.
    Sci Rep; 2020 Nov 18; 10(1):20119. PubMed ID: 33208771
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.